FIELD: medicine.
SUBSTANCE: present claim relates to the use of a nitrogen oxide-releasing agent in the production of a drug for the prevention or treatment of diseases or disorders related to the administration of VEGFR inhibitor and/or VEGF inhibitor. The present claim additionally provides a method for the prevention or treatment of diseases or disorders related to the administration of VEGFR inhibitor and/or VEGF inhibitor to an object, including administration of prophylactically or therapeutically effective amount of the nitrogen oxide-releasing agent to the object in need of it.
EFFECT: obtaining an agent for the treatment of side effects in tumor therapy.
30 cl, 28 dwg, 18 tbl, 159 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OPHTHALMOLOGICAL PHARMACEUTICAL COMPOSITIONS FOR NEOANGIOGENIC EYE PATHOLOGIES | 2009 |
|
RU2519739C2 |
| USING ALLOPURINOL FOR TREATING PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME | 2010 |
|
RU2543325C2 |
| METHOD OF RENAL CELL CARCINOMA TREATMENT USING N-(4-(6,7-DIMETHOXYQUINOLINE-4-ILOXY)PHENYL)-N' - (4-FLUOROPHENYL)CYCLOPROPANE-1,1-DICARBOXAMIDE, (2S) - HYDROXYBUTANEDIOATE | 2017 |
|
RU2748549C2 |
| METHOD OF TREATING PALMAR-PLANTAR ERYTHRODYSESTHESIA | 2018 |
|
RU2722396C2 |
| ANTHRANILIC ACID AMIDES, METHOD FOR THEIR PREPARING AND THEIR USING, METHOD FOR TREATMENT OF NEOPLASM DISEASE AMD PHARMACEUTICAL DRUG POSSESSING INHIBITORY ACTIVITY WITH RESPECT TO TYROSINE KINASE VEGF RECEPTOR | 2002 |
|
RU2318811C2 |
| MICROEMULSION COMPOSITIONS | 2019 |
|
RU2787998C1 |
| PYRIDINE DERIVATIVES AS INHIBITORS OF VASCULAR ENDOTHELIUM GROWTH FACTOR RECEPTORS 2 (VEGFR-2) AND PROTEIN TYROSINE KINASE | 2009 |
|
RU2522444C2 |
| INHIBITORS OF RECEPTORS OF TYPE 2 VESSEL ENDOTHELIUM GROWTH FACTOR | 2004 |
|
RU2402567C2 |
| TREATING CANCER WITH COMBINATION OF RADIATION THERAPY, CERIUM OXIDE NANOPARTICLES AND CHEMOTHERAPEUTIC AGENT | 2015 |
|
RU2704811C2 |
| PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
